Vista Capital Management Sues Illumina for More than $10M Over Rejection of Roche | GenomeWeb

NEW YORK (GenomeWeb News) – A substantial investor in Illumina's stock is suing the company alleging breach of fiduciary duty in connection with Roche's efforts to buy the San Diego-based company and its efforts to fend off that approach.

In a lawsuit filed with the US District Court, Southern District of New York this week, the plaintiffs, Vista Capital Management, seeks damages of more than $10 million.

Based in Geneva, Vista is a privately held financial services firm that owned more than 300,000 shares of Illumina stock during the periods covered by its lawsuit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.